Undetectable MRD and Extended PFS More Common with MRD-guided Ibrutinib-Venetoclax than with Ibrutinib Alone or FCR Regimen Among Patients with CLL By Ogkologos - October 13, 2025 19 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FLAIR study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Pembrolizumab Now Second Immunotherapy Approved to Treat Merkel Cell Carcinoma February 4, 2019 3 ways we’re helping teenagers and young adults with cancer April 18, 2023 Nivolumab-Based Combinations Improve Survival in Advanced Esophageal Cancer June 17, 2021 EMA Recommends Granting a Conditional Marketing Authorisation for Belantamab Mafodotin July 29, 2020 Load more HOT NEWS An Alternative Model for Genetic Testing Delivery Proposed with Posttest Counselling... Young Mom-of-Three Learns She Has Stage 4 Breast Cancer, 5 Days... Cancer Research UK publishes gender and ethnicity pay gap reports It’s a fair COP: Why our chief clinician went to a...
